Together, these results suggest that pharmacological inhibition of NLRP3 may inactivate myeloid cell subpopulation associated with ARVC (Mye2) to solve to the inflammation and fibrosis of ARVC. The gene discussed is NLRP3; the disease is Arrhythmogenic right ventricular dysplasia.